have you heard of STRVC I have been following him
Post# of 1007
(Total Views: 667)
Posted On: 04/08/2017 4:16:10 PM
have you heard of STRVC I have been following him since 2000 a great voyeur, this what he said about INOH a great read
INOH & Israel Medical Marijuana Connection Possibility
INOH is finally beginning to wake up as confirmation of their recent submission of a lot of filings to obtain OTC Markets Pink Current Information Status. The question is... Why? I believe it's because they now have a very solid and legitimate story to tell going forward of which I believe we are in its infant stages for receiving significant updates to confirm future growth.
INOH is based out of Colorado which we all know is well known for its marijuana/cannabis approvals/authorizations exiting for the state. Also, there is a connection that INOH has with providing medical support to Israel which is considered the medical marijuana capital of the world to some.
Below is some older news from a deal that INOH had done with Regulon, Inc. which I believe coupled with INOH has some huge Israel connections that could evolve within the medical marijuana realm to go along with their partnership regarding the Regulon proven medicine for cancer that is in Phase III with its drug known as Lipoplatin, which is the same drug under the name Nanoplatin for non-small cell lung cancer (NSCLC), has shown success in all cancer indications tested thus far (NSCLC, pancreatic, urinary bladder, gastric, breast, head & neck cancers):
Quote:
http://www.marketwired.com/press-release/in-o...974879.htm
Recent studies showed that platinum-based chemotherapy drugs share is growing. The platinum drug market is anticipated to increase tremendously after cisplatin, a cytotoxin agent, is replaced by Regulon's LipoPlatin™. Regulon is a private biopharmaceutical company committed to the discovery and development of nano-pharmaceutics in oncology which has raised over $30,000,000 in the private marketplace in countries including Greece, Cyprus, Austria, Turkey, Korea, Brazil, Taiwan, Israel, and Lebanon.
Teni Boulikas, PhD., President and CEO of Regulon, stated: "After establishing a solid base in Europe and breaking into the Asian market, we are pleased to partner with INOH. We view this relationship as symbiotic, offering INOH's clients cancer solutions from detection to treatment. We look forward to the introduction of Regulon's products to the Caribbean markets."
Mark Goldberg, Co-CEO of INOH, added: "After the recent phase of technology acquisition by INOH culminating in the launching of sputum cytology products, developed by Mel Ehrlich, Ph.D., reaching end-users is our primary goal." Co-CEO Rosendo Alvarez, III added, "We are thrilled to enter this association with Regulon and to augment our companies' offerings to purchasers of cancer-related technologies. The mutual introduction to additional markets is the beginning of a new phase with significant growth potential for both companies."
INOH & Israel Medical Marijuana Connection Possibility
INOH is finally beginning to wake up as confirmation of their recent submission of a lot of filings to obtain OTC Markets Pink Current Information Status. The question is... Why? I believe it's because they now have a very solid and legitimate story to tell going forward of which I believe we are in its infant stages for receiving significant updates to confirm future growth.
INOH is based out of Colorado which we all know is well known for its marijuana/cannabis approvals/authorizations exiting for the state. Also, there is a connection that INOH has with providing medical support to Israel which is considered the medical marijuana capital of the world to some.
Below is some older news from a deal that INOH had done with Regulon, Inc. which I believe coupled with INOH has some huge Israel connections that could evolve within the medical marijuana realm to go along with their partnership regarding the Regulon proven medicine for cancer that is in Phase III with its drug known as Lipoplatin, which is the same drug under the name Nanoplatin for non-small cell lung cancer (NSCLC), has shown success in all cancer indications tested thus far (NSCLC, pancreatic, urinary bladder, gastric, breast, head & neck cancers):
Quote:
http://www.marketwired.com/press-release/in-o...974879.htm
Recent studies showed that platinum-based chemotherapy drugs share is growing. The platinum drug market is anticipated to increase tremendously after cisplatin, a cytotoxin agent, is replaced by Regulon's LipoPlatin™. Regulon is a private biopharmaceutical company committed to the discovery and development of nano-pharmaceutics in oncology which has raised over $30,000,000 in the private marketplace in countries including Greece, Cyprus, Austria, Turkey, Korea, Brazil, Taiwan, Israel, and Lebanon.
Teni Boulikas, PhD., President and CEO of Regulon, stated: "After establishing a solid base in Europe and breaking into the Asian market, we are pleased to partner with INOH. We view this relationship as symbiotic, offering INOH's clients cancer solutions from detection to treatment. We look forward to the introduction of Regulon's products to the Caribbean markets."
Mark Goldberg, Co-CEO of INOH, added: "After the recent phase of technology acquisition by INOH culminating in the launching of sputum cytology products, developed by Mel Ehrlich, Ph.D., reaching end-users is our primary goal." Co-CEO Rosendo Alvarez, III added, "We are thrilled to enter this association with Regulon and to augment our companies' offerings to purchasers of cancer-related technologies. The mutual introduction to additional markets is the beginning of a new phase with significant growth potential for both companies."
(0)
(0)